Verifying…
本页为自动翻译。剂量和警告请以英文原文为准。 阅读英文版
Home / Registered in Nigeria / Newflend ND H9

Newflend ND H9

NAFDAC Reg. No. A6-100208 · Drug

Registered with NAFDAC. Registration activeAs of 20 November 2026 · synced automatically from official sources.
Product
Newflend ND H9
NAFDAC number
A6-100208
Active ingredient
Recombinant turkey herpesvirus expressing Newcastle disease and H9 avian influenza antigens (rHVT/ND/H9), Live
Strength
3,000 - 12,000 PFU per dose
Form
Concentrate for suspension for injection
Pack size
2 mL x 2000 doses (in glass ampoule)
Manufacturer
Not listed
Applicant (holder)
Ceva Animal Health Pvt Ltd
Approved
30 Jul 2025
Status
Active View on NAFDAC ↗
Registration valid to
29 Jul 2030
WHO alerts
None found
Community reports
None
Times checked
0

About the medicine: Live: uses, dosage and brands worldwide

What we found

  • Newflend ND H9 is on the NAFDAC register with an active registration (A6-100208). A valid number alone does not prove a pack is genuine — counterfeiters copy real numbers, so also check the expiry date, seal and print quality.

Generated automatically from the NAFDAC register, WHO alerts and community data as of today. This is not medical advice. Always follow your doctor or pharmacist.

How to use Newflend ND H9

What the official label says. If a doctor prescribed it, follow the prescription. Your pack's leaflet comes first if it is different.

Who it is for

ALTUVIIIO is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a recombinant DNA-derived, Factor VIII concentrate indicated for use in adults and children with hemophilia A (congenital factor VIII deficiency) for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment & control of bleeding episodes Perioperative management of bleeding ( 1 ) Limitation of Use: ALTUVIIIO …

How to take it and how often
  • For intravenous use after reconstitution only
  • For intravenous use only
  • Each ALTUVIIIO vial label states Factor VIII activity in international units (IU or unit)
  • For routine prophylaxis: 50 IU/kg once weekly
  • For on-demand treatment and control of bleeding episodes and perioperative management: 50 IU/kg Estimated Increment of Factor VIII (IU/dL or % of normal) = 50 IU/kg × 2 (IU/dL per IU/kg) To achieve a specific target Factor VIII activity level, use the following formula: Dosage (IU) = Body Weight (kg) × Desired Factor VIII Increase (IU/dL or % normal) × 0.5 (IU/kg per IU/dL)
  • Dose Each ALTUVIIIO vial label states the Factor VIII potency in international units (IU)
  • One IU corresponds to the Factor VIII activity contained in one milliliter of normal human plasma, as defined by the current World Health Organization (WHO) international standard for Factor VIII concentrate
  • Potency assignment for ALTUVIIIO is determined using an activated partial thromboplastin time (aPTT)-based one-stage clotting assay
  • It is recommended to use a validated one-stage clotting assay to measure ALTUVIIIO Factor VIII activity in plasma
  • The ALTUVIIIO Factor VIII activity level is overestimated by the chromogenic assay and a specific ellagic acid based aPTT reagent in one-stage clotting assay by approximately 2.5-fold [see Warnings and Precautions ]. …
Strengths it comes in

ALTUVIIIO is available as a white to off-white lyophilized powder for reconstitution in single-dose vials containing nominally 250, 500, 750, 1000, 2000, 3000, or 4000 international units (IU) per vial. For injection: nominally 250, 500, 750, 1000, 2000, 3000, or 4000 IU, lyophilized powder in single-dose vials for reconstitution. ( 3 )

Children
  • The safety and effectiveness of ALTUVIIIO for routine prophylaxis, on-demand treatment, and perioperative management of bleeding episodes have been established
  • In pediatric patients
Older adults

Clinical studies of ALTUVIIIO did not include sufficient numbers of patients 65 years of age and older to determine whether or not such patients respond differently from younger patients. However, clinical experience with other Factor VIII products has not identified differences between the elderly and younger patients.

While you are taking it
  • Advise the patients to: Read the FDA-approved patient labeling (Patient Information and Instructions for Use)
  • Call their healthcare provider or go to the emergency department right away if a hypersensitivity reaction occurs
  • Early signs of hypersensitivity reactions may include rash, hives, itching, facial swelling, tightness of the chest, and wheezing
  • Contact their healthcare provider or treatment facility for further treatment and/or assessment if they experience a lack of a clinical response to Factor VIII therapy because this may be a sign of inhibitor development
Talk to a doctor first if
  • ALTUVIIIO is contraindicated in patients who have had severe hypersensitivity reactions, including anaphylaxis, to the product or its excipients [see Description ]
  • Do not use in patients who have had severe hypersensitivity reactions, including anaphylaxis, to ALTUVIIIO or excipients of ALTUVIIIO
Warnings

Hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO. If symptoms occur, immediately discontinue ALTUVIIIO and initiate appropriate treatment. ( 5.1 ) Neutralizing antibodies (inhibitors) to Factor VIII have been reported. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. ( 5.2 , 5.3 ) 5.1 Hypersensitivity Reactions Hypersensitivity reactions, including anaphylaxis, have occurred with ALTUVIIIO [see Postmarketing Experience (6.2) ] . …

Possible side effects

Most common adverse reactions (incidence >10%) are headache and arthralgia. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Bioverativ Therapeutics Inc. (A SANOFI COMPANY) at 1-800-633-1610 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety data described in this section reflects exposure to ALTUVIIIO in two clinical studies, Study 1 and Study 2 and are pooled for analysis. …

Pregnancy and breastfeeding

8.1 Pregnancy Risk Summary There are no data with ALTUVIIIO use in pregnant women to inform a drug-associated risk. Animal developmental and reproductive studies have not been conducted with ALTUVIIIO. Therefore, it is not known whether ALTUVIIIO can affect reproductive capacity or cause fetal harm when given to pregnant women. In the U.S. …

How to store it

Prior to reconstitution: Store ALTUVIIIO in the original package to protect the ALTUVIIIO vials from light. Store ALTUVIIIO in powder form at 2°C to 8°C (36°F to 46°F). Do not freeze to avoid damage to the prefilled diluent syringe. …

If you miss a dose

Take it when you remember, unless it is nearly time for the next dose. Then skip the missed one. Never take two doses at once to make up for it. Check your leaflet, as some medicines are different.

From the official U.S. FDA label for this active ingredient. Your pack may have a different strength, so always read its leaflet. If a doctor prescribed it, follow the prescription. Ask a pharmacist if you are unsure. Label dated 2026-10-20.

Label for recombinant turkey herpesvirus expressing newcastle disease and h and nd and h and live, the active ingredient registered with NAFDAC.

Check your pack of Newflend ND H9

Add the expiry date on your pack for a full Trust Score.

Or take photos of the pack
3 free checks left today Official sources: U.S. FDA · EMA (EU) · Health Canada · WHO alerts

About Newflend ND H9

What is in Newflend ND H9?

Newflend ND H9 contains Recombinant turkey herpesvirus expressing Newcastle disease and H9 avian influenza antigens (rHVT/ND/H9), Live (3,000 - 12,000 PFU per dose), as concentrate for suspension for injection, according to its NAFDAC registration record.

Is Newflend ND H9 registered with NAFDAC?

Yes. Newflend ND H9 is listed on the NAFDAC register under registration number A6-100208, and its registration is active as of 20 November 2026.

Has Newflend ND H9 been flagged as fake or recalled?

No WHO falsified or substandard medical product alert currently matches Newflend ND H9 in our automatically synced alert list.

How can I check that my pack of Newflend ND H9 is genuine?

Run a free authenticity scan with the NAFDAC number A6-100208, your pack's expiry date and batch number to get a Trust Score, compare the pack with the NAFDAC record (ingredient, strength, form, manufacturer), and buy only from licensed pharmacies.

How do I take Newflend ND H9?

Follow your prescription or the leaflet in your pack. The official label says: For intravenous use after reconstitution only. For intravenous use only. Each ALTUVIIIO vial label states Factor VIII activity in international units (IU or unit). ( 2.1 ) For routine prophylaxis: 50 IU/kg once weekly. ( 2.1 ) For on-demand treatment and control of bleeding episodes and perioperative management: 50 IU/kg ( 2.1 ) Estimated Increment of Factor VIII (IU/dL or % of…

What is Newflend ND H9 used for?

ALTUVIIIO is indicated for use in adults and pediatric patients with hemophilia A (congenital factor VIII deficiency) for: Routine prophylaxis to reduce the frequency of bleeding episodes On-demand treatment and control of bleeding episodes Perioperative management of bleeding ALTUVIIIO [antihemophilic factor (recombinant), Fc-VWF-XTEN fusion protein-ehtl] is a recombinant DNA-derived, Factor VIII (Summarised from the official U.S. FDA label for recombinant turkey herpesvirus expressing newcastle disease and h and nd and h and live. Always follow your doctor or pharmacist.)

Patient reviews

–No reviews yet
5★
0
4★
0
3★
0
2★
0
1★
0
Have you used Newflend ND H9? Share your experience to help other patients. Sign in to review

Reviews are personal experiences from PillVera users, not medical advice. Report side effects to your doctor and to NAFDAC.